Reported about 9 hours ago
Moderna Inc.'s shares rose following a smaller-than-expected third-quarter loss due to effective cost-cutting measures as Covid vaccine sales decline significantly. The company reduced its forecast for future sales and faced challenges with new vaccine guidelines limiting access to shots. Despite experiencing a drop in revenue, Moderna aims to break even by 2028 and is expanding into new vaccine markets, including cancer and flu.
Source: YAHOO